Glaucoma in our days: Reselling concepts and costs;Glaucoma dos nossos dias: Revendo conceitos e custos

Revista Brasileira de Oftalmologia

Volumn 62, Issue 9, 2003, Pages 669-677

  De Arruda Mello, Paulo Augusto ^a,b   Soares Melo Jr , Luiz Alberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPIVEFRINE; DISTIGMINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; UNOPROSTONE ISOPROPYL ESTER;

AGE DISTRIBUTION; CHRONIC DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GLAUCOMA; GLAUCOMA SURGERY; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH STATISTICS; HUMAN; PATHOPHYSIOLOGY; POPULATION RISK; PREVALENCE; PROGNOSIS; REVIEW; SEX RATIO; TREATMENT INDICATION; VISUAL IMPAIRMENT;

EID: 0345169997     PISSN: 00347280     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130(4):429-40.
2. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology 2001;108(2):247-53.
3. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):714-20.
4. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-79.
5. Urbano AP, Freitas TG, Arcieri ES, Urbano AP, Costa VP. Avaliação dos tipos de glaucoma no serviço de oftalmologia da Unicamp. Arq Bras Oftalmol 2003;66(1):61-5.
6. Dawson B, Trapp RG. Basic & Clinical Biostatistics. New York: Lange Medical Books/McGraw-Hill; 3 ed, 2001.
7. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983;118(2):166-91.
8. Leske MC, Ederer F, Podgor M. Estimating incidence from age-specific prevalence in glaucoma. Am J Epidemiol 1981;113(5):606-13.
9. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38(1):83-91.
10. Wu SY, Nemesure B, Leske MC. Observed versus indirect estimates of incidence of open-angle glaucoma. Am J Epidemiol 2001;153(2):184-7.
11. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977;106(1):17-32.
12. Kahn HA, Milton RC. Revised Framingham eye study prevalence of glaucoma and diabetic retinopathy. Am J Epidemiol 1980;111(6):769-76.
13. Leske MC, Connell AM, Wu SY, Nemesure B, Li X, Schachat A, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001;119(1):89-95.
14. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80(5):389-93.
15. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994;101(11):1851-5.
16. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109(8):1090-5.
17. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325(20):1412-7.
18. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. Jama 1991;266(3):369-74.
19. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103(10):1661-9.
20. IBGE. Censo demográfico 2000. Disponfvel em: http://www.ibge.com.br.
21. Póvoa CA, Nicolela MT, Valle ALSL, Gomes LES, Neustein I. Prevalência de glaucoma identificada em campanha de detecção em São Paulo. Arq Bras Oftalmol 2001;64:303-7.
22. Michelson G, Groh MJ. Screening models for glaucoma. Curr Opin Ophthalmol 2001;12(2):105-11.
23. Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 2002;120(6):804-11.
24. Niessen AG, Langerhorst CT, Geijssen HC, Greve EL. Design of low cost glaucoma screening. Doc Ophthalmol 1997;93(4):293-315.
25. Doyle JW, Smith MF, Tierney JW Jr. Glaucoma medical treatment - 2002: does yearly cost now equal the year? Optom Vis Sci 2002;79(8):489-92.
26. Stewart WC, Sine C, Cate E, Minno GE, Hunt HH. Daily cost of beta-adrenergic blocker therapy. Arch Ophthalmol 1997;115(7):853-6.
27. Ikeda H, Sato E, Kitaura T, Fukuchi H, Kimura Y, Kihira K. Daily cost of ophthalmic solutions for treating glaucoma in Japan. Jpn J Ophthalmol 2001;45(1):99-102.
28. Fiscella RG, Geller JL, Gryz LL, Wilensky J, Viana M. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 1999;128(4):426-33.
29. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236(11):811-21.
30. Vaidergorn PG, Susannna Jr R, Leal BC, Villela FF. Desperdício no uso de colírios por pacientes portadores de glaucoma. Rev Bras Oftal 2001;60(4):271-6.
31. Roizenblatt R, Freitas D, Belfort Jr R, Hofling-Lima AL, Prata Jr JA. Impacto econômico no tratamento do glaucoma: volume de gotas de colírios antiglaucomatosos brasileiros e norte-americanos. Arq Bras Oftalmol 2001;64:143-6.
32. Vold SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma 2000;9(2):150-3.
33. Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 2001;79(3):286-8.
34. Pedroso L, Carvalho Jr ES, Paranhos Jr A, Prata Jr JA, Mello PAA. Custo real do tratamento do glaucoma para o paciente. Arq Bras Oftalmol 1999;62(6):677-82.
35. Silva LMS, Vasconcellos JPC, Temporini ER, Costa VP, Kara-José N. Tratamento clínico do glaucoma em um hospital universitário: custo mensal e impacto na renda familiar. Arq Bras Oftalmol 2002;65:299-303.
36. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997;115(6):777-84.
37. Parrish RK 2nd, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione CM, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997;115(11):1447-55.
38. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF, McGorray S. Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 1998;105(3):561-6.
39. Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998;105(11):2112-6.
40. Lee BL, Wilson MR. Health-related quality of life in patients with cataract and glaucoma. J Glaucoma 2000;9(1):87-94.
41. Jampel HD. Glaucoma patients' assessment of their visual function and quality of life. Trans Am Ophthalmol Soc 2001;99:301-17.
42. Green J, Siddall H, Murdoch I. Learning to live with glaucoma: a qualitative study of diagnosis and the impact of sight loss. Soc Sci Med 2002;55(2):257-67.
43. West SK. Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol Rev 2000;22(1):64-70.
44. Pena JD, Mello PAA, Hernandez MR. Synthesis of elastic microfibrillar components fibrillin-1 and fibrillin-2 by human optic nerve head astrocytes in situ and in vitro. Exp Eye Res 2000;70(5):589-601.
45. Parc C, Johnson DH. Physiology of aqueous humor outflow resistance: its relation to giant vacuoles. J Fr Ophtalmol 2003;26(2):198-201.
46. Skaf M, di Martino DS, Mello PAA, Varma R. Adenoviral-mediated gene transfer to the filtering bleb in rabbits. J Glaucoma 2001;10(6):470-6.
47. Borras T. Recent developments in ocular gene therapy. Exp Eye Res 2003;76(6):643-52.
48. Borras T. Gene expression in the trabecular meshwork and the influence of intraocular pressure. Prog Retin Eye Res 2003;22(4):435-63.
49. Vasconcellos JP, Melo MB, Schimiti R, Costa FF, Costa VP. Penetrance and phenotype of the Cys433Arg myocilin mutation in a family pedigree with primary open-angle glaucoma. J Glaucoma 2003;12(2):104-7.
50. Kanamori A, Nakamura M, Escano MF, Seya R, Maeda H, Negi A. Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am J Ophthalmol 2003;135(4):513-20.
51. Weinreb RN, Bowd C, Zangwill LM. Glaucoma detection using scanning laser polarimetry with variable corneal polarization compensation. Arch Ophthalmol 2003;121(2):218-24.
52. Miyake K, Uchida H, Sugiyama K, Yamamoto T, Kitazawa Y, Shinohara H. Quantification of retinal nerve fiber defects in glaucoma: three-dimensional analysis by Heidelberg retina tomograph. Jpn J Ophthalmol 2003;47(4):347-50.
53. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 2003;110(2):359-62.
54. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003;44(8):3394-401.
55. Costa VP, Almeida GV, Kara-José N. Prevenção da cegueira por glaucoma. Arq Bras Oftalmol 1998;61(3):356-60.